Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5292]

Antisense oligonucleotide therapy may be a new potential treatment for H3.3K27M diffuse midline glioma

Antisense oligonucleotide therapy may be a new potential treatment for H3.3K27M diffuse midline glioma

New study flips the script on liver cancer

New study flips the script on liver cancer

NCCN Annual Conference brings up important questions for improving cancer care

NCCN Annual Conference brings up important questions for improving cancer care

Precision magnetics could be game-changer for therapy-resistant brain cancers

Precision magnetics could be game-changer for therapy-resistant brain cancers

Gene scissors find target for testicular cancer therapy

Gene scissors find target for testicular cancer therapy

New therapy harnesses patients’ blood cells to fight tumours

New therapy harnesses patients’ blood cells to fight tumours

Combination therapy overcomes BET inhibitor resistance

Combination therapy overcomes BET inhibitor resistance

Easy and quick binding of targeting molecule and radiotracer to drug nanocarrier for cancer therapy

Easy and quick binding of targeting molecule and radiotracer to drug nanocarrier for cancer therapy

Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer

FDA converts to full approval indication for pembrolizumab for certain adult and paediatric patients with advanced microsatellite instability-High (MSI-H) or mismatch repair deficient (dMMR) solid tumours

FDA converts to full approval indication for pembrolizumab for certain adult and paediatric patients with advanced...

More from ecancer